A groundbreaking study reveals a strong demand for new male contraceptives worldwide. Researchers surveyed over 18,000 men and 9,000 women across seven countries, uncovering widespread interest in male birth control options. The findings suggest male contraceptives could transform family planning and promote gender equity in reproductive health.
Two years ago, the Parsemus Foundation partnered with NEXT Life Sciences to prepare Vasalgel — the non-hormonal, long-lasting, and reversible male contraceptive — for human
The Male Contraceptive Initiative celebrates its 10-year anniversary this year! The U.S.-based nonprofit organization is a leading funder and advocate for male contraception. Their stated
NEXT Life Sciences announced that world-renowned vasectomy doctors have joined its medical advisory board, marking significant progress toward making a long-lasting, non-hormonal, reversible contraceptive available
The promise of new male contraceptive options was highlighted in an article by Kelcie Moseley-Morris published in News from the States. Heather Vahdat of the
The Parsemus Foundation founder and trustee, Elaine Lissner, was invited to speak about male contraception at the SXSW event on March 10, 2023. SXSW (“south
NEXT Life Sciences, Inc. announced on March 22, 2023 its plans for the Plan A™ male contraceptive. Vasalgel, the polymer hydrogel developed by the Parsemus
The Parsemus Foundation and Revolution Contraceptives LLC are pleased to announce that NEXT Life Sciences, Inc. has been selected to continue development of the Vasalgel
Elaine Lissner, founder of the Parsemus Foundation, recently participated in an ideation workshop in San Francisco for the Male Contraceptive Initiative (MCI). The goal of
Revolution Contraceptives received a $200,000 grant from the Male Contraceptive Initiative (MCI) to advance Vasalgel towards human trials. The grant will support preclinical studies that
And if you don’t find a match there, this slightly more complex clinical trials finder includes studies sponsored by companies as well:
